Place of Origin: | CN |
Brand Name: | WWHS |
Certification: | CE |
Model Number: | CRP |
Minimum Order Quantity: | 1000 |
---|---|
Price: | US 1.50 - 2.50 Kit |
Packaging Details: | Colorful Paper Box |
Delivery Time: | 7 Days |
Payment Terms: | T/T |
Supply Ability: | 50000 Kits per Week |
Product Name: | CRP Rapid Test Kit | Manufacturer: | WWHS Biotech INC |
---|---|---|---|
Usage: | Inflammation Detection | Package: | 25T |
Advantage: | High Accuracy | Application In: | WWHS NIR-1000 Dry Fluoroimmunoassay Analyser |
Throughput: | 3000 Tests/Day | Reactivity: | Human |
Keywords: | High Sensitive, Best Stability | Annual Capacity: | 3 Million A Year |
High Light: | Inflammation Detection Rapid Quantitative Test Kits,25T Package CRP Rapid Test Kit,CE Approved CRP Rapid Test Kit |
【Product name】 CRP.pdf
Diagnostic Kit for C-reactive Protein (Immunochromatographic assay)
【Test principle】
The kit is used the principle of fluorescence immunochromatography. The CRP antigen in the sample first combines with the fluorescent labeled CRP monoclonal antibody conjugate, and then continues to move and combine with another CRP monoclonal antibody fixed on the nitrocellulose membrane to form a double antibody sandwich immune complex at the detection line of nitrocellulose membrane. The quantitative detection results are obtained by NIR-1000 dry fluoroimmunoassay analyser.
【Main components】
name | Loading capacity | component |
Test card | 25 | It is composed of fluorescent pad (coated with fluorescent labeled CRP monoclonal antibody), nitrocellulose membrane (coated with CRP monoclonal antibody and Goat anti mouse IgG antibody), absorbent paper and backing |
Sample diluent | 25 | Phosphate buffer |
ID card | 1 | Record the standard curve information of this batch of reagents |
The components in different batches of kits cannot be used interchangeably.
【Sample requirements】
1. Serum and EDTA•Na2 anticoagulant plasma and whole blood, EDTA•K2 anticoagulant plasma and whole blood, sodium citrate anticoagulant plasma and whole blood can be used.
2. Venous blood was collected according to routine laboratory methods, and hemolysis was avoided as much as possible in the process of treatment.
3. After clinical samples were collected, the detection was completed within 4 hours at room temperature (15-30) ℃.The whole blood sample can be stored for 24 hours at (2-8)℃ without freezing; Serum and plasma samples can be stored for 7 days at 2-8℃;Serum and plasma samples - 20℃ for 30 days.
4. The sample must return to room temperature (15-30)℃ before testing. The frozen samples should be completely thawed, rewarming and mixed evenly before use, and repeated freezing and thawing should be avoided.
5. Do not test samples with severe hemolysis, severe lipidemia and jaundice.
【Performance】
1. Detection limit: No higer than 0.5mg/L.
2. Accuracy: the relative deviation from the target value is not more than±10%.
3. Repeatability: coefficient of variation (CV) should be no more than 10%.
4. Inter batch difference: the relative range (R) between batches should be no more than 15%.
5. Linear range: within the specified linear range of 0.5mg/l-200mg/l, the linear correlation coefficient R ≥ 0.990.The absolute deviation of the linear range in [0.5-5] mg/L is not more than ±5 mg/L, the linear range is (5-200] mg/L, the relative deviation is less than±10%.
cat#. | Product Item | Specimen | Reaction Time | Measure Range | Clinical Range | Itended Use |
Cardiac | ||||||
1 | cTnI | WB/Serum/Plasma | 12min. | 0.1-40ng/ml | <0.3ng/ml | several heart diseases including myocardial infarction and heart failure. |
2 | Myo | WB/Serum/Plasma | 12min. | 5-400ng/ml | <58ng/ml | acute myocardial infarction (AMI) in early stage. |
3 | CK-MB | WB/Serum/Plasma | 12min. | 1-200ng/ml | <5ng/ml | acute myocardial infarction (AMI) in early stage. |
4 | NT-proBNP | WB/Serum/Plasma | 10min. | 20-35000pg/ml | Under 75:0~347pg/mL, Over 75:0~449pg/mL |
heart failure . |
5 | D-Dimer | WB/Plasma | 10min. | 40-10000ng/ml | <500ng/ml | disseminated intravascular coagulation (DIC),deep vein thrombosis (DVT),pulmonary embolism (PE), myocardial infarction, cerebral infarction, etc. |
6 | cTnI+Myo+CKMB | WB/Serum/Plasma | 12min. | same with single item | same with single item | Triple marker of myocardial infarction. |
7 | ST2 | WB/Serum/Plasma | 10min. | 10-400ng/ml | <35ng/ml | heart failure . |
8 | Lp-PLA2 | WB/Serum/Plasma | 10min. | 10-900ng/ml | <175ng/ml | Risk evaluation of ACS and atherosclerotic ischemic stroke patients. |
9 | S100-β | WB/Serum/Plasma | 10min. | 0.05-10ng/ml | <0.2ng/ml | Cerebral infarction, cerebral injury. |
Inflammation | ||||||
10 | CRP / hs-CRP | WB/Serum/Plasma | 3min. | 0.5-200mg/L | CRP<10mg/L,hs-CRP<1mg/L | nonspecficity inflammatory marker. |
11 | SAA | Serum | 5min. | 1-200mg/L | <10mg/L | inflammation&infection. |
12 | PCT | WB/Serum/Plasma | 10min. | 0.2-100ng/ml | <0.5ng/ml | Sepsis |
13 | CRP+SAA | WB/Serum/Plasma | 5min. | same with single item | same with single item | inflammation&infection. |
14 | IL-6 | WB/Serum/Plasma | 10min. | 5-4000pg/ml | 10pg/ml | diabetes,rheumatoid arthritis,etc |
Thyroid Hormone | ||||||
15 | TSH | Serum/Plasma | 15min. | 0.3-100mU/L | 0.35-5mU/L | hyperthyroidism and hypothyroidism |
16 | TT3 | Serum/Plasma | 15min. | 0.5-10nmol/L | 1.3-3.1nmol/L | thyroid dysfunction |
17 | TT4 | Serum/Plasma | 15min. | 5-300nmol/L | 66-181nmol/L | thyroid dysfunction |
18 | FT3 | Serum/Plasma | 15min. | 1-100pmol/L | 4-10pmol/L | thyroid dysfunction |
19 | FT4 | Serum/Plasma | 15min. | 5-300pmol/L | 19-39pmol/L | thyroid dysfunction |
Tumor Marker | ||||||
20 | AFP | Serum/Plasma | 15min. | 2.5-200ng/ml | <20ng/ml | pregnancy cancer |
21 | CEA | Serum/Plasma | 15min. | 1-200ng/ml | <5ng/ml | colon cancer, colorectal cancer,etc. |
22 | NSE | Serum/Plasma | 15min. | 1-400ng/ml | <16ng/ml | non-small cell lung cancer |
23 | FOB | fecal specimens | 10min. | 50-1000ng/ml | <100ng/ml | Abnormal recessive gastrointestinal bleeding |
24 | PG II | Serum/Plasma | 15min. | 1-100ug/L | PGI/PGII>3.0 | gastric abnormalities |
25 | PG I | Serum/Plasma | 15min. | 2.5-200ug/L | >70ng/ml | gastric abnormalities |
26 | TPSA | Serum/Plasma | 15min. | 0.5-40ng/ml | <4ng/ml | prostate cancer |
27 | FPSA | Serum/Plasma | 15min. | 0.1-10ng/ml | <1ng/ml | prostate cancer |
28 | CA12-5 | Serum/Plasma | 15min. | 20-500U/ml | <35U/ml | ovarian cancer |
29 | CA15-3 | Serum/Plasma | 15min. | 10-400U/ml | < 25 U/mL | breast cancer |
30 | HE4 | Serum/Plasma | 15min. | 50-2000pmol/L | <140 pmol/L | ovarian cancer |
31 | CA19-9 | Serum/Plasma | 15min. | 10-400U/ml | < 27 U/mL | pancreatic cancer |
32 | β-HCG | Serum/Plasma | 15min. | 5-400mIU/ml | <10 mIU/mL | Early pregrancy, ectopic HCG cancer,incomplete abortion |
33 | CK19(Cyfra21-1) | Serum/Plasma | 15min. | 0.5-50ng/ml | <2.5ng/ml | non-small cell lung cancer |
Fertility | ||||||
34 | HCG / β-HCG | Serum/Plasma | 10min. | 5-20000mIU/ml | <5 mIU/mL | early pregrancy. |
35 | AMH | Serum/Plasma | 10min. | 0.1-16ng/ml | Male: 20-60 years old, 0.92-13.89 ng/mL Female: 20-29 years old, 0.88-10.35 ng/mL 30-39 years old, 0.31-7.86 ng/mL 40 -50 years old, <5. 07 ng/mL |
ovarian reserve level |
36 | LH | Serum/Plasma | 20min. | 1-200mIU/ml | Male: 1.70-8.60 mIU/mL; Female: Follicular phase : 2.95 13.65 mIU/mL Ovulation phase: 13.65-95.75 Miu/mL Luteal phase: 1.25-11.00 mIU/mL Menopause phase: 8.24 -55.23 mIU/mL |
reproductive dysfunction |
37 | FSH | Serum/Plasma | 20min. | 1-100mIU/ml | Male: 1.50-12.40 mIU/mL Female: Follicular phase : 4.46-12.43 mIU/mL Ovulation phase: 4.88-20.96 mIU/mL Luteal phase: 1 .96-7.70 mIU/mL Menopause phase: 22.70-130.00 mIU/mL |
reproductive system |
38 | Testosterone | Serum/Plasma | 20min. | 0.25-16ng/ml | Male: 20-49 years old, 1.61-8.41 ng/mL >50 years old, <0.61 ng/mL Female: 20-49 years old, <0.80ng/mL >50 years old, <0.71 ng/mL |
sexual hormone disturbance and hypogonadism. |
39 | Progesterone | Serum/Plasma | 20min. | 1-50ng/ml | pregrancy progesterone | |
40 | PRL | Serum/Plasma | 20min. | 1-200ng/ml | Female (non-pregnant): 4.60-25.07 ng/mL Male: 3.45-17.42 ng/mL | breastfeeding&abnormal lactation |
41 | SHBG | Serum/Plasma | 20min. | 1-200nmol/L | 15-120nmol/L | unphysiological diseases. |
42 | E2 | Serum/Plasma | 20min. | 10-1000pg/ml | Male: <85 pg/mL Female: Follicular Phase: 12-262 pg/mL Ovulation: 40-396 pg/mL Luteal Phase: 21-381 pg/mL Menopause: <190 pg/mL Pregnancy: >145 pg/mL |
ovarian vitality. |
Gastrointestinal | ||||||
43 | FOB | fecal specimens | 10min. | qualitative | qualitative | gastrointestinal hemorrhage. |
44 | TRF | fecal specimens | 10min. | qualitative | qualitative | gastrointestinal hemorrhage. |
45 | FOB+TRF | fecal specimens | 10min. | qualitative | qualitative | gastrointestinal hemorrhage. |
Infection | ||||||
46 | Covid-19 Antigen | nasal swab, throat swab or nasal wash/aspirate specimens | 15min. | qualitative | qualitative | respiratory tract |
47 | Covid-19 Ab IgG/IgM | WB/Serum/Plasma | 15min. | qualitative | qualitative | respiratory tract |
48 | FluA | nasal swab, throat swab or nasal wash/aspirate specimens | 15min. | qualitative | qualitative | respiratory tract |
49 | FluB | nasal swab, throat swab or nasal wash/aspirate specimens | 15min. | qualitative | qualitative | respiratory tract |
Renal injury | ||||||
50 | CysC | WB/Serum/Plasma | 5min. | 0.4-9mg/L | 0.5-1.1mg/L | renal function |
51 | NGAL | Urine | 10min. | 10-1500ng/mL | <132ng/mL | acute kidney injury. |
Other | ||||||
52 | FERR | Serum | 5min. | 10-500ng/ml | Male:24ng/mL~335ng/mL, Female:11ng/mL~307ng/mL |
iron metabolism related diseases, such as hemochromatosis and iron deficiency anemia |
53 | HbA1c | WB | 10min. | 4%-14% | 4%-6% | diabetes |
54 | VD | Serum/Plasma | 15min. | 8-70ng/mL | 19-57ng/mL | fetation |
Contact Person: sales
Tel: +8613823276027
Address: Rm 505, 1st Building, Shenzhen Biomedicine Innovation Industrial Park, No. 14th, Jinhui Road, East Jinxiu Road, Kengzi Street, Pingshan District, Shenzhen
Factory Address:Rm 505, 1st Building, Shenzhen Biomedicine Innovation Industrial Park, No. 14th, Jinhui Road, East Jinxiu Road, Kengzi Street, Pingshan District, Shenzhen